Trevi Therapeutics reports promising results for Oral Nalbuphine in human abuse potential study
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced positive oral nalbuphine results from its human abuse potential (HAP) study evaluating the investigational therapy Haduvio™ for ... Read More
CHMP endorses Merck’s gefapixant for EU approval for chronic cough treatment
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approval for gefapixant, an investigational, non-narcotic, oral selective P2X3 receptor ... Read More
GSK to acquire Canadian biopharma company BELLUS Health for $2bn
GSK has agreed to acquire BELLUS Health, a Canadian biopharma company, in a deal worth around $2 billion in a move to further bolster its ... Read More